Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse

NCT06736613 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06736613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
December 11, 2024
Completion date
December 11, 2027
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, diffuse large b cell lymphoma of breast, diffuse large b cell lymphoma of testis, dlbcl - diffuse large b cell lymphoma, double expressor dlbcl, high-grade b-cell lymphoma, hiv-associated diffuse large b cell lymphoma, intravascular large b-cell lymphoma, stage iii high grade b-cell lymphoma, stage iv high grade b-cell lymphoma